News Releases

2020

R&D
May.27.2020
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (134KB)
Products
May.20.2020
Launch of Velexbru® Tablet 80mg, a Bruton’s Tyrosine Kinase Inhibitor in Japan (221KB)
R&D
May.18.2020
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1% (157KB)
R&D
May.14.2020
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic Non-Small Cell Lung Cancer in CheckMate -9LA Study (116KB)
R&D
May.14.2020
Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ≥1% (153KB)
R&D
May.14.2020
ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Treatment of Previously Untreated Unresectable Advanced or Recurrent Gastric Cancer in Japan (118KB)
Management / Finance
May.12.2020
Ono establishes a specified subsidiary and a local subsidiary in the US (120KB)
Management / Finance
May.12.2020
Announcement on Financial Results for FY2019
R&D
Apr.21.2020
Ono and Takeda Announce Results from Phase 3 CheckMate -9ER Study for Opdivo® (Nivolumab) and CABOMETYX® (Cabozantinib) Combination Therapy in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (188KB)
R&D
Apr.21.2020
Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma (116KB)
R&D
Apr.13.2020
Opdivo® (Nivolumab) Intravenous Infusion Approved for Additional Indication of Unresectable Advanced or Recurrent Squamous Cell Carcinoma of Esophageal cancer in South Korea (142KB)
R&D
Apr.13.2020
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-mutant Metastatic Colorectal Cancer (CRC) after Prior Therapy (144KB)
R&D
Apr.09.2020
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer (116KB)
Corporate
Apr.08.2020
Announcement on Election of Provisional Audit & Supervisory Board Member (Temporary Acting Audit & Supervisory Board Member) (135KB)
Corporate
Apr.06.2020
Announcement on Candidates of Members of the Board of Directors, Members of Audit & Supervisory Board and Corporate Officers, and Resignation of Audit & Supervisory Board Member (115KB)
Licensing
Mar.30.2020
ONO Enters into a New Research and Option Agreement with Numab (126KB)
R&D
Mar.26.2020
ONO and BMSKK Submit Supplemental Application for Opdivo plus Yervoy in Combination Treatment with Chemotherapy in Japan to Expand the Use for First-Line Treatment of Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer (206KB)
R&D
Mar.25.2020
ONO Receives a Manufacturing and Marketing Approval for Velexbru® Tablet 80mg, a BTK inhibitor, for Treatment of Recurrent or Refractory Primary Central Nervous System Lymphoma in Japan (132KB)
R&D
Mar.12.2020
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib (117KB)
Licensing
Mar.05.2020
ONO and Nichi-Iko Enter into Licensing Agreement and Technical Collaboration for Limaprost Alfadex Tablets (95.7KB)
R&D
Mar.04.2020
ONO Submits Supplemental Application of BRAFTOVI® Capsule, a BRAF Inhibitor and MEKTOVI® Tablet, a MEK Inhibitor for Additional Indication of Unresectable, Advanced or Recurrent BRAF-Mutant Colorectal Cancer in Japan (115KB)
CSR
Mar.03.2020
ONO First Selected as a "2020 Health & Productivity Stock" (377KB)
R&D
Feb.27.2020
ONO Submits Supplemental Application for Approval for Opdivo® (Nivolumab) to Expand the Use for Treatment of Unresectable Advanced or Recurrent Non-small Cell Lung Cancer, in Combination Treatment with Chemotherapy in Japan (200KB)
R&D
Feb.21.2020
ONO Receives Approval of Opdivo® (Nivolumab) for Additional Indications of Unresectable Advanced or Recurrent Esophageal Cancer, and MSI-High Unresectable Advanced or Recurrent Colorectal Cancer in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval (178KB)
R&D
Feb.21.2020
BMSKK and ONO Receive Approval of Orencia® for I.V. Infusion,
Orencia® Syringe for S.C. Injection and Orencia® Auto-injector for S.C. Injection,
a Selective T-cell Co-Stimulation Modulator in Japan, to Include the Description of Prevention of Structural Damage of Joints in Current Indication of Rheumatoid Arthritis (152KB)
R&D
Feb.17.2020
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma (116KB)
R&D
Feb.17.2020
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (118KB)
R&D
Feb.03.2020
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (139KB)
Management / Finance
Jan.31.2020
Announcement on Financial Results for FY2019 3Q
R&D
Jan.24.2020
ONO Announces Result from Phase III Clinical Study Evaluating Opdivo® (Nivolumab) in Patients with Platinum-Refractory Advanced or Recurrent Ovarian Cancer (113KB)
CSR
Jan.20.2020
ONO Selected as a "Climate Change A List" Company in CDP 2019 for Two Consecutive Years (215KB)
R&D
Jan.16.2020
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer (116KB)
R&D
Jan.06.2020
Ono and Seikagaku Submit a New Drug Application for Manufacturing and Marketing Approval for ONO-5704/SI-613 for the Treatment of Osteoarthritis in Japan (207KB)